Baxter International (BAX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is a low bar with a clear narrative — management guided to earnings "similar to Q1" (~$0.37 adj. EPS) with slight volume improvement, and consensus is sitting right at that level; the bigger swing factor is whether the ~500 bps H1-to-H2 margin bridge remains credible, making any incremental color on absorption roll-through, Novum, and injectables supply the real market-moving variables.

Heading into Q2 2026, the bar for Baxter is deliberately low: management explicitly guided to Q2 adjusted EPS "similar to Q1" (~$0.37) with only slight volume improvement, and consensus at ~$0.37 sits squarely in line with that framing, leaving little room for a meaningful beat on the bottom line but also limiting downside risk from a miss. The more consequential question is whether the company can sustain confidence in its second-half inflection thesis — a ~500 bps operating margin expansion from H1 to H2 driven by volume seasonality (~250 bps), cost structure actions (~125 bps), and the roll-through of elevated inventory produced in H2 2025 (~125 bps). Estimate revisions have been broadly stable since the Q1 print on April 30, with the Q2 EPS consensus ticking up modestly from ~$0.31 post-Q1 to ~$0.37 currently, suggesting the street has largely re-rated to management's own framing. The stock has rallied sharply — up ~38% over the past three months and ~13% in the past month — driven almost entirely by multiple re-expansion (EV/EBITDA from ~7.5x to ~8.7x) rather than estimate upgrades, meaning the stock has already priced in a degree of turnaround credibility that the print must now validate. The single biggest wildcard is the Novum LVP ship hold — any signal of resolution (or conversely, material customer returns) would be the most asymmetric catalyst in either direction — followed closely by the contract manufacturer supply disruption in injectables, which management flagged as persisting into 2027 and which remains an unresolved drag on the Pharmaceuticals segment now folded into MPT.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low bar on EPS (~$0.37, in line with management's own Q2 guide) and a modest bar on revenue (~$2.79B vs. $2.81B in Q2 2025); the bigger swing factor is adjusted operating margin — Q2 is expected to be the trough before the H2 inflection, and any upside or downside surprise there will set the tone for full-year credibility.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data (Total Revenue, EPS, EBITDA, ITT, MPT, Pharmaceuticals, FCF); Q1 2026 Earnings Call transcript (April 30, 2026); Q2 2026 Segment Recast 8-K (July 14, 2026). Adj. Operating Margin Q2 2026 implied from management's "similar to Q1" guidance. Q2 2025 adj. EPS of $0.54 per VA actuals.

Table 2 — Beat / Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Total Revenue

KPI 2: Adjusted EPS (Diluted, Continuing Operations)

Pattern: BAX has beaten on revenue in 4 of the last 5 quarters with available comparable data, but EPS history is more mixed — large beats when the bar is reset low (Q4 2024, Q1 2025, Q1 2026) and meaningful misses when consensus was anchored too high (Q2 2025, Q4 2025); the current Q2 2026 setup mirrors the "reset low" pattern, which historically has favored a beat.

Source: Visible Alpha Consensus and Actuals Data. Note: Q2 2024 and Q3 2024 revenue consensus figures are not directly comparable due to the July 14, 2026 segment recast (8-K); those periods are excluded from the beat/miss analysis to avoid misleading comparisons.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been fully reiterated at every post-Q1 touchpoint (BofA Healthcare Conference May 13, Goldman Sachs Healthcare Conference June 9) with no numerical changes; tone has shifted modestly more constructive on the H2 margin bridge and IV solutions normalization, but the Novum hold and injectables supply disruption remain the two unresolved overhangs embedded in guidance.

Sources: BAX Q1 2026 Earnings Call transcript (April 30, 2026); BAX at BofA Global Healthcare Conference transcript (May 13, 2026); BAX at Goldman Sachs Global Healthcare Conference transcript (June 9, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved modestly higher since the Q1 print — Q2 EPS consensus rose from ~$0.31 to ~$0.37 as the street re-anchored to management's "similar to Q1" framing — but FY2026 EPS consensus at ~$1.91 sits at the low end of the $1.85–$2.05 guidance range, reflecting lingering skepticism about H2 delivery; the gap between guidance midpoint ($1.95) and consensus ($1.91) is a modest cushion, not a risk.

Commentary: Estimates have been remarkably stable since the Q1 print, with the street essentially locking in management's own Q2 framing. The modest downward drift in EBITDA and FCF estimates (−1.6% and −5.0% respectively) suggests the market is slightly more cautious than guidance on cost absorption and working capital, but the gap is not large enough to represent a meaningful risk. The key test is whether Q2 results sustain confidence in the H2 bridge — if absorption headwinds prove stickier than guided, FY EPS consensus could drift toward the low end of the $1.85–$2.05 range.

Source: Visible Alpha Consensus and Actuals Data (all estimate figures); BAX Q1 2026 Earnings Call (April 30, 2026) for guidance figures.

5. Stock Performance

Key Takeaway: BAX's ~38% rally over the past three months has been driven almost entirely by multiple re-expansion (EV/EBITDA from ~7.5x to ~8.7x NTM) rather than estimate upgrades, meaning the stock has re-rated on turnaround credibility — a fragile foundation that requires Q2 results to validate the H2 margin bridge.

Current NTM Multiples (as of July 29, 2026): EV/EBITDA 8.67x | EV/Sales 1.74x | P/E 12.60x | P/FCF 17.55x | P/Sales 1.10x

Sector ETF Reference: IHI (iShares U.S. Medical Devices ETF) is the most appropriate sub-sector benchmark for BAX given its diversified medical device and hospital supply portfolio. Over the past 3 months, BAX has significantly outperformed the broader medtech peer group, driven by the turnaround re-rating following the Q1 2026 beat and guidance reiteration on April 30, 2026.

Key Events Since Last Earnings (April 30, 2026):

• April 30, 2026: Q1 2026 earnings beat; guidance reiterated; stock rallied meaningfully on the day.
• May 8, 2026: 8-K filed — shareholders approved 20M share incentive plan; executive severance plan updated.
• May 13, 2026: BofA Global Healthcare Conference — management reiterated FY2026 guidance; confirmed comfort with H2 bridge; IV solutions characterized as "new norm."
• June 9, 2026: Goldman Sachs Global Healthcare Conference — guidance reiterated; ~$50M absorption headwind in Q2 flagged; tariff lapping expected in H2.
• July 14, 2026: 8-K segment recast filed — Pharmaceuticals folded into MPT's ITP division; new two-segment structure (MPT + HST) effective Q2 2026; historical data recast for comparability.
• July 9, 2026: BAX announced Q2 2026 earnings call scheduled for July 29, 2026.

Source: Stock performance decomposition data from internal analytics; BAX 8-K filings; conference transcripts.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 14 segment recast — folding Pharmaceuticals into MPT's ITP division and moving to a two-segment structure effective Q2 2026 — which changes how investors will read the Q2 print and requires recalibration of prior-period comparisons; operationally, no new guidance changes have been issued.

• July 14, 2026 — Segment Recast (8-K): BAX filed an 8-K recasting historical segment financials to reflect a new two-segment structure effective Q2 2026: Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST). The former Pharmaceuticals segment is now reported within MPT's Infusion Therapies & Platforms (ITP) division. Certain shared corporate costs previously allocated to segments will now remain unallocated.
• Implication: Q2 2026 will be the first quarter reported under the new structure; prior-period comparisons require use of the recast tables in Exhibit 99.1. Investors should not compare Q2 2026 segment results directly to previously published Q2 2025 segment figures without adjustment.
• July 9, 2026 — Q2 Earnings Call Announcement: BAX confirmed Q2 2026 results will be released July 29, 2026 with a conference call for investors. No pre-announcement or guidance update was included.
• June 9, 2026 — Goldman Sachs Global Healthcare Conference: CEO Andrew Hider and IR head Kevin Moran reiterated FY2026 guidance in full. Key incremental disclosures: (1) absorption headwind of ~$50M in Q2 (vs. ~$20M in Q1), expected to be fully behind the company exiting H1; (2) tariff headwinds expected to begin lapping in H2; (3) IV solutions characterized as "the new norm" with low single-digit growth expected in future years; (4) contract manufacturer supply disruption in injectables remains a "key focus" with no resolution timeline given; (5) Ahmedabad facility approved for new injectable product launches.
• May 13, 2026 — BofA Global Healthcare Conference: Management reaffirmed full-year guidance and provided additional color on the H2 margin bridge. CEO Hider confirmed IV solutions demand has been "rightsized" and the business is expected to return to low single-digit growth. Dynamo stretcher launch described as receiving "tremendous feedback." Free cash flow improvement characterized as "a nice area of improvement" in Q1 but "not where we want it to be."
• May 8, 2026 — Shareholder Meeting / 8-K: Shareholders approved a 20 million share incentive plan increase. Executive severance plan and certificate of incorporation were also updated.
• Implication: The incentive plan expansion signals management's intent to retain and incentivize talent through the turnaround; the severance update may reflect ongoing organizational restructuring under CEO Hider.
• April 30, 2026 — Q1 2026 Earnings Beat & Guidance Reiteration: BAX reported Q1 revenue of $2.701B (+3% reported, −1% organic) and adj. EPS of $0.37, both ahead of consensus. Free cash flow of $76M was a significant positive surprise vs. −$221M in Q1 2025. Full-year guidance reiterated in full. No material Novum returns in Q1. CFO Joel Grade's departure (announced March 2026) confirmed; Anita Zielinski serving as interim CFO.
• Ongoing — Novum LVP Ship & Installation Hold: The hold on Baxter's Novum large-volume pump remains in place and is assumed to persist for all of 2026. Management is working to finalize hardware and software corrections. No material customer returns were observed in Q1, but the risk remains embedded in guidance. This is the single largest known headwind to ITT revenue.
• Ongoing — Contract Manufacturer Supply Disruption (Injectables): A supply disruption at an external contract manufacturer for injectable products was disclosed in Q1 and is expected to limit supply into 2027. Management is on-site working with the manufacturer but has not provided a resolution timeline. This is a compounding headwind on top of existing softness in premix products and inhaled anesthesia.
• Ongoing — CFO Transition: Joel Grade departed as CFO in March 2026. Anita Zielinski is serving as interim CFO. No permanent successor has been announced. A CFO search is presumably underway, though management has not provided a timeline.

7. Peer Commentary — Current-Quarter Read-Through

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for BAX's Q2 setup — hospital procedure volumes are healthy (ISRG, HAE), U.S. capital spending is stable (ISRG), and supply chain/tariff headwinds are manageable (HAE, RMD) — but ISRG's flag on U.S. procedure moderation in deferrable cases due to ACA subsidy changes is a watch item for BAX's HST segment.

Methodology Note: Only commentary from the last 60 days (on or after May 29, 2026) that speaks to the current reporting quarter (Q2 2026, ending June 30, 2026) or the forward outlook is included below. Excluded: (1) peer Q1 2026 earnings calls discussing Q1 results (backward-looking); (2) any commentary predating May 29, 2026 (outside the 60-day window). BAX's own conference appearances (BofA May 13, GS June 9) are covered in Section 3 and Section 6 and are not repeated here. The BAX-specific read-through from the BofA conference (May 13) is excluded as it falls outside the 60-day window.

Intuitive Surgical (ISRG) — Q2 2026 Earnings Call (July 16, 2026)

Relevance to BAX: HIGH. ISRG is the most directly relevant peer read-through given its Q2 2026 results speak to current hospital procedure volumes, capital spending, and the macro environment for medical devices in the exact same quarter BAX is reporting.

• Hospital Procedure Volumes — Healthy but Moderating in Deferrable Cases: ISRG reported total procedures up 16% in Q2 2026 (Da Vinci +15%, Ion +36%). However, U.S. Da Vinci growth moderated to +12%, "predominantly in procedures that can be deferred," attributed to the expiration of ACA enhanced premium subsidies affecting patient coverage and timing of care. ISRG maintained its full-year Da Vinci procedure growth guidance of 13.5%–15.5%.
• BAX Read-Through: Overall hospital volumes remain healthy, which is supportive of BAX's infusion consumables and acute care demand. However, the moderation in deferrable procedures is a watch item for BAX's HST segment (Front Line Care, Care & Connectivity Solutions), where management already guided H1 to be pressured with growth back-half weighted. The ACA subsidy dynamic is a new incremental headwind not previously flagged by BAX management.
• U.S. Capital Spending — Stable: ISRG described Q2 as "a strong capital quarter" with 468 Da Vinci systems placed (+18% YoY). The U.S. capital environment was characterized as "stable for some time now," with ~70% of U.S. systems under leasing arrangements providing flexibility. Some customers expressed caution over ACA enrollment trends but this had not impacted ISRG's pipeline.
• BAX Read-Through: Stable U.S. hospital capital spending is a positive read-through for BAX's HST segment, particularly the Care & Connectivity Solutions division (smart beds, patient monitoring) and the Dynamo stretcher launch. BAX management had noted at the GS conference (June 9) that it had "not observed a slowdown in U.S. hospital capital spending." ISRG's Q2 data validates that view.
• Supply Chain / Tariffs — Ongoing but Manageable: ISRG received a $36M pre-tax benefit from a refund of previously paid tariffs in Q2. Looking forward, ISRG continues to expect "higher input costs in certain areas, including freight and semiconductor memory" for the remainder of 2026.
• BAX Read-Through: The ongoing freight and semiconductor cost pressures flagged by ISRG are consistent with BAX's own tariff headwind guidance (~$80M gross for FY2026). BAX management noted at the GS conference that tariff headwinds will begin lapping in H2 2026, which aligns with ISRG's experience. The chip shortage risk is relevant to BAX's infusion pump and connected care device portfolio.
• China — Challenging: ISRG noted "lower tender activity, increased domestic robotic competition and policy driven pricing pressure" in China, with centralized procurement (VBP-style) for surgical equipment being introduced.
• BAX Read-Through: BAX has already announced the exit of IV solutions in China (reflected in organic growth calculations). The broader China policy environment remains a headwind for any remaining BAX exposure in that market.
• Cost Pressures on Hospitals: ISRG announced plans to introduce an "extended use program" in H1 2027 to lower customer cost per procedure for high-volume benign procedures, signaling that hospital cost pressure is a structural theme.
• BAX Read-Through: This reinforces the competitive pressure BAX faces to demonstrate value in high-volume consumable categories (IV solutions, infusion sets). It also validates BAX's strategy of combining Pharma with ITT to simplify the customer workflow and reduce friction.

Haemonetics (HAE) — Goldman Sachs Global Healthcare Conference (June 8, 2026)

Relevance to BAX: MODERATE-HIGH. HAE operates in adjacent acute care and hospital markets (blood management, interventional technology). Commentary from June 8 falls within the 60-day window and speaks to Q2 2026 conditions.

• Hospital Procedure Volumes — Very Healthy: HAE CEO Christopher Simon stated "we don't see any of it [slowdown]. We see very healthy volumes" across general cardiology, cardiac surgery, interventional cardiology, transplant, and trauma. AFib access site growth expected to accelerate from ~3.5% in 2025 to 6%–7% in 2026, with a path to double-digit growth.
• BAX Read-Through: Strongly positive for BAX's acute care and infusion consumables demand. Healthy surgical and acute care volumes support utilization of BAX's IV solutions, infusion systems, and acute therapy products. The robust cardiac surgery and transplant volumes are particularly relevant to BAX's Advanced Surgery (hemostats/sealants) business within MPT.
• Supply Chain / Tariffs — Conservative Planning: HAE noted it has "held it together and beat back tariffs and inflation and geopolitical disruption" over the past four years and has been "very conservative" in planning for tariff and inflation costs.
• BAX Read-Through: Consistent with BAX's own approach of embedding tariff headwinds conservatively in guidance. The fact that HAE has successfully managed these pressures suggests BAX's ~$80M gross tariff estimate is a reasonable planning assumption.
• Margin Expansion Thesis: HAE CEO noted that "gross margin is not done," with volumes and mix "trending favorably" and operating leverage expected to "begin to manifest pretty materially this year."
• BAX Read-Through: Supportive of BAX's own H2 margin expansion thesis. If a peer in adjacent hospital markets is seeing operating leverage materialize from volume and mix improvement, it lends credibility to BAX's ~500 bps H1-to-H2 margin bridge.

ResMed (RMD) — William Blair Growth Stock Conference (June 2, 2026)

Relevance to BAX: LOW-MODERATE. RMD is a respiratory/sleep device company with limited direct overlap with BAX's core businesses. Commentary from June 2 falls within the 60-day window. Read-through is primarily thematic (supply chain, digital efficiency, hospital staffing).

• Supply Chain Flexibility: RMD CEO Michael Farrell highlighted the company's "supply chain flexibility," stating it can deliver products to 144 countries regardless of geopolitical disruptions (Strait of Hormuz, cost pressures).
• BAX Read-Through: Thematic read-through — supply chain resilience is a sector-wide priority. BAX's own supply chain challenges (contract manufacturer disruption in injectables) are company-specific rather than systemic, which is somewhat reassuring.
• Digital Efficiency / Staffing: RMD reported a 50% reduction in labor costs for patient setup using its digital portfolio and a 70% reduction in healthcare provider time per patient in the UK NHS. GLP-1 drugs described as a "huge tailwind" for RMD over the next 1–5 years.
• BAX Read-Through: The digital efficiency theme is relevant to BAX's Connected Care Foundation and HST segment strategy. GLP-1 impact on bariatric procedures (flagged by ISRG as a headwind) is a watch item for BAX's surgical consumables, though BAX's exposure is primarily through hemostats/sealants in non-bariatric procedures.

Excluded Peer Commentary — Rationale

8. Insider Transaction Activity

Key Takeaway: No open-market insider buy or sell activity has been identified in the available data for the period since the Q1 2026 earnings call (April 30, 2026); the absence of discretionary selling by insiders ahead of the Q2 print is a mild positive signal, though the ongoing CFO vacancy and interim leadership may limit the signal value.

Note: The May 8, 2026 8-K disclosed shareholder approval of a 20 million share incentive plan increase and updates to executive severance arrangements. These are plan-level corporate actions, not individual open-market transactions, and are therefore not included in the table above. The CFO role remains in transition (Anita Zielinski serving as interim CFO following Joel Grade's March 2026 departure), which may reduce the signal value of insider activity data for this period.

9. Risks & Key Questions for Management

Key Risks

• Novum LVP Hold Resolution / Customer Returns (HIGH): The ship and installation hold is assumed in place for all of 2026. Any material customer returns or competitive losses during the hold period would be a direct revenue headwind to ITT and could impair the H2 recovery thesis. Conversely, any resolution signal would be the most asymmetric positive catalyst.
• H2 Margin Bridge Execution (HIGH): The ~500 bps H1-to-H2 operating margin expansion is the central investment thesis. It depends on three simultaneous drivers: volume seasonality, cost structure actions, and inventory roll-through. If any one of these is delayed or smaller than guided, FY EPS could fall toward the low end of the $1.85–$2.05 range or below.
• Injectables Supply Disruption (MEDIUM-HIGH): The contract manufacturer supply disruption is expected to persist into 2027. This is a multi-quarter headwind on a segment (now folded into MPT's ITP division) that was already facing softness in premix products and inhaled anesthesia. Any worsening of the supply situation would be incremental negative.
• IV Solutions Demand Baseline (MEDIUM): Management has characterized the post-hurricane IV conservation as "the new norm" and rightsized the business accordingly. If the new baseline proves lower than expected, or if hospital ordering patterns remain erratic, the ITT segment could underperform even the reset guidance.
• Tariff and Macro Headwinds (MEDIUM): BAX has guided ~$80M gross tariff impact for FY2026. Escalation in trade policy, higher oil prices, or broader inflationary pressures could exceed this estimate. Management noted tariff lapping begins in H2, but any new tariff actions could reset the baseline.
• ACA Subsidy Expiration / Hospital Volume Softness (MEDIUM): ISRG flagged moderation in deferrable U.S. procedures due to ACA enhanced premium subsidy expiration. While BAX's consumables are less deferrable than elective surgery, any sustained softening in hospital admissions or procedure volumes would pressure ITT and HST.
• CFO Vacancy (LOW-MEDIUM): The CFO role has been vacant since March 2026 with Anita Zielinski serving as interim. A prolonged vacancy could create uncertainty around financial strategy, capital allocation execution, and investor confidence in the turnaround narrative.
• Segment Recast Comparability (LOW): The July 14 recast changes how Q2 2026 results will be presented vs. prior periods. Investors and analysts who have not updated their models to the new two-segment structure may misread the Q2 print. This is a presentation risk, not an operational one.

Key Questions for Management

1. Novum LVP: What is the current status of hardware and software corrections? Have you seen any incremental customer returns or competitive losses during Q2? Is there any updated timeline for resolution?
2. H2 Margin Bridge: Can you confirm that the ~$50M absorption headwind in Q2 has fully cleared as expected? Are the cost structure actions from January fully realized? What gives you confidence in the volume seasonality assumption for H2?
3. Injectables Supply: Has the contract manufacturer supply situation improved, stabilized, or worsened since Q1? Is there a path to resolution before 2027, and what is the revenue impact if supply remains constrained?
4. IV Solutions Demand: Has the new demand baseline stabilized in Q2, or are you still seeing ordering variability? When do you expect to see the low single-digit growth trajectory resume?
5. New Segment Structure: With Pharmaceuticals now folded into MPT's ITP division, how should investors think about the margin profile of the combined ITP division vs. the prior standalone Pharmaceuticals segment? Will you provide ITP-level margin disclosure?
6. CFO Search: What is the timeline for naming a permanent CFO? Is the interim CFO empowered to make capital allocation decisions, including the debt paydown path to sub-3x leverage?
7. 2027 Outlook: With TSA income rolling off (~$0.14/share headwind), can you provide more specificity on the cost actions already taken to offset this? Is the "modest earnings growth" in 2027 still the right framing?
8. Capital Allocation: Are you on track to reach ~3x net leverage by year-end 2026? Once achieved, what is the sequencing of the five capital allocation levers (debt, buybacks, internal investment, M&A, dividend)?